As of 2025-04-23, the Intrinsic Value of Humanigen Inc (HGEN) is -406.46 USD. This HGEN valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.04 USD, the upside of Humanigen Inc is -1,126,023.80%.
Based on its market price of 0.04 USD and our intrinsic valuation, Humanigen Inc (HGEN) is overvalued by 1,126,023.80%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| DCF (Growth 5y) | (941.96) - (313.21) | (450.68) | -1248512.8% |
| DCF (Growth 10y) | (327.49) - (912.06) | (456.32) | -1264141.0% |
| DCF (EBITDA 5y) | (259.36) - (304.12) | (1,234.50) | -123450.0% |
| DCF (EBITDA 10y) | (283.92) - (344.48) | (1,234.50) | -123450.0% |
| Fair Value | -406.46 - -406.46 | -406.46 | -1,126,023.80% |
| P/E | (2,207.88) - (2,697.26) | (2,686.69) | -7442455.9% |
| EV/EBITDA | (1,521.70) - (880.89) | (1,145.17) | -3172305.6% |
| EPV | (1,663.53) - (2,182.52) | (1,923.02) | -5327023.0% |
| DDM - Stable | (625.06) - (2,468.98) | (1,547.01) | -4285454.3% |
| DDM - Multi | (124.58) - (401.09) | (192.32) | -532842.7% |
| Market Cap (mil) | 0.02 |
| Beta | -4.25 |
| Outstanding shares (mil) | 0.66 |
| Enterprise Value (mil) | -3.08 |
| Market risk premium | 5.00% |
| Cost of Equity | 10.03% |
| Cost of Debt | 7.00% |
| WACC | 7.59% |